Getting your player ready...
Merck & Co. plans to cut as many as 13,000 more jobs under a new round of restructuring as the drugmaker prepares for generic competition next year for its top-selling drug — asthma and allergy medicine Singulair — and slower growth in the U.S. and Europe.
The announcement came Friday as Merck reported a higher second-quarter profit than a year ago. Merck’s net income was $2.02 billion, or 65 cents a share, up from $752 million or 24 cents a share, a year earlier. Revenue totaled $12.15 billion, up 7 percent.
